Collaborative Agreement, Additional Milestone Payment

No definition available.

Name:	opk_CollaborativeAgreementAdditionalMilestonePayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement. Maximum Milestone Payments

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangement.MaximumMilestonePayments
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Grant Repayment

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangementGrantRepayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Milestone Payment

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangementMilestonePayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Milestone Payment Received

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangementMilestonePaymentReceived
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Upfront Payment

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Estimated milestone payment to be received.

+ References

No definition available.

+ Details

Name:	opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License and Collaboration Agreements Proceeds as Up Front Payment

+ References

No definition available.

+ Details

Name:	opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Payments Under License Agreements

+ References

No definition available.

+ Details

Name:	opk_PaymentsUnderLicenseAgreements
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue From Sale Of Intellectual Property

+ References

No definition available.

+ Details

Name:	opk_RevenueFromSaleOfIntellectualProperty
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Estimated amount of loss resulting from an adverse tax position.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (d)(3)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

+ Details

Name:	us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

+ Details

Name:	us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=opk_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=opk_TesaroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_RxiPharmaceuticalsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Strategic Alliances (Details) (USD $)	3 Months Ended		1 Months Ended
Strategic Alliances (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Jan. 31, 2015	Dec. 31, 2010	Dec. 31, 2014	Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue	$ 288,800,000us-gaap_DeferredRevenue				$ 6,700,000us-gaap_DeferredRevenue
Liability for Uncertain Tax Positions, Current	2,300,000
Grant repayment	25,889,000	0
Pfizer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from sale of intellectual property	12,500,000
Pfizer [Member] \| Collaborative Arrangement, Product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment			295,000,000
Additional milestone payment to be received			275,000,000
Revenue from sale of intellectual property	12,500,000
Deferred revenue	282,500,000
Grant repayment	25,900,000
Tesaro [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments under license agreements				121,000,000
Upfront payment under license agreements				6,000,000
Milestone payment received	5,000,000
Additional milestone payment	25,000,000
Accrued Liabilities [Member] \| Pfizer [Member] \| Collaborative Arrangement, Product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue	70,600,000
Other Noncurrent Liabilities [Member] \| Pfizer [Member] \| Collaborative Arrangement, Product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue	211,900,000
Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Estimate of possible loss	0
Minimum \| Pfizer [Member] \| Collaborative Arrangement, Product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment ranges			20,000,000
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Estimate of possible loss	50,000,000
Maximum \| Pfizer [Member] \| Collaborative Arrangement, Product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment ranges			90,000,000
Rxi Pharmaceuticals Corporation [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments						$ 50,000,000